Invitrogen™ VEGF-D (FIGF) Human ELISA Kit

Descripción

The Human Vascular Endothelial Growth Factor D (Hu VEGFD/FIGF) ELISA quantitates Hu VEGFD in human serum, plasma, or cell culture medium. The assay will exclusively recognize both natural and recombinant Hu VEGFD. Principle of the method The Human VEGFD solid-phase sandwich ELISA (enzyme-linked immunosorbent assay) is designed to measure the amount of the target bound between a matched antibody pair. A target-specific antibody has been pre-coated in the wells of the supplied microplate. Samples, standards, or controls are then added into these wells and bind to the immobilized (capture) antibody. The sandwich is formed by the addition of the second (detector) antibody, a substrate solution is added that reacts with the enzyme-antibody-target complex to produce measurable signal. The intensity of this signal is directly proportional to the concentration of target present in the original specimen. Rigorous validation Each manufactured lot of this ELISA kit is quality tested for criteria such as sensitivity, specificity, precision, and lot-to-lot consistency. See manual for more information on validation.

Several forms of VEGF have been identified, including VEGF, VEGF-B, VEGF-C and VEGF-D (also designated FIGF). Characteristic of VEGF proteins, the central region of VEGF-D contains eight cysteine residues. These residues are essential for homodimerization. VEGFD may play a role in tumor progression, as it is induced by c-Fos, which is required for conversion of early stage tumors to malignant tumors. It has been observed that overexpression of VEGF-D induces morphological changes in fibroblasts.